Breast Cancer

For Shvon Lowe, an invitation from a friend to attend the Sisters Network 5K turned into being something much bigger in her life.

Language and cultural barriers should not keep a patient from receiving and understanding their cancer care. SHARE Cancer Support steps in for people who face this struggle.

3-D mammograms are now getting a better look at breasts, meaning cancer is spotted more easily and there are less women unnecessarily called back for unnecessary imaging.

A good attitude means so much more than a smile to cancer patients.

Transitioning from breast cancer patient to survivor can be challenging, but here are some practical tips to help make it easier.

Getting new prostheses can be emotional and challenging, but it doesn't have to be!

According to a recent study, many patients with breast cancer are getting sent for unnecessary imaging.

The U.S. Food and Drug Administration has approved Ibrance for use in combination with Faslodex in pretreated patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Women in their teens and early adulthood may be able to reduce their risk of breast cancer by eating a diet rich in fiber, according to a recent study.

Fellow cancer survivor Melisa Etheridge's song "I Run for Life" has gained a permanent spot on my running playlist because it reminds me why I run.

At the end of the day, it is the patient who gets to decide what kind of medical treatment is best for them. Doctors may not always like their choice.

Explaining our cancer to the rest of the world.

We should not assume that people diagnosed with metastatic disease will want to quit work. We need to ask patients with newly diagnosed metastatic disease how they view and value their jobs.

Hope? Several years out, a breast cancer and melanoma survivor contemplates what comforted her and could have comforted at the time of diagnosis and early in her treatment.

Am I alone in wanting to reassure everyone I meet?

The designation, which will expedite the development and review of sacituzumab govitecan in TNBC, is based on a phase 2 trial in which the therapy induced a response rate of 31 percent in heavily pretreated patients with metastatic TNBC.